Actively Recruiting
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Led by University Hospital, Akershus · Updated on 2023-03-17
60
Participants Needed
1
Research Sites
654 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Akershus
Lead Sponsor
C
ChromaDex, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.
CONDITIONS
Official Title
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy
- Eastern Cooperative Oncology Group performance status 0-2
You will not qualify if you...
- Age under 18 years
- Acute myocardial infarction within the last three months
- Participation in another pharmaceutical clinical trial of an investigational medicinal product less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer
- Conditions affecting compliance with the study protocol such as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers
- Life expectancy less than 6 months
- Known allergy to any of the components in the Nicotinamide Riboside (Niagen�) tablet
- Contraindications or inability to undergo cardiac magnetic resonance (CMR) examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Akershus University Hospital
Lørenskog, Akershus, Norway, 1478
Actively Recruiting
Research Team
T
Torbjørn Omland, MD, PhD
CONTACT
V
Victoria Vinje, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here